MMS Holdings (MMS) has been selected by Friends of Cancer Research (Friends) to support the development of practical decision frameworks to inform the interpretation of interim overall survival (OS) data in oncology clinical trials.
Cancer Research | 20/08/2025 | By Dineshwori
Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML
Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death
Cancer Research | 13/06/2022 | By Sudeep Soparkar | 731
Researchers develop machine learning prog ikarus to identify cancer cells
Data from lung and colorectal cancer cells were used to train the algorithm before applying it to data sets of other kinds of tumours
Cancer Research | 13/06/2022 | By Sudeep Soparkar | 848
Porvair Sciences displays examine units and microplates for Cancer Research
Porvair Sciences will display its measure packs and microplates for malignant growth and life science research at the American Association for Cancer Research (AACR) meeting in New Orleans, USA from the eighth - thirteenth April 2022.
Cancer Research | 16/04/2022 | By Sudeep Soparkar | 754
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy